摘要
细胞凋亡是肝脏疾病发病机制中的一个显著的特点。肝细胞凋亡的分子机制还不清楚。肝损伤诱导下调肝细胞核因子6(HNF6)是与细胞凋亡程度呈负相关。然而,肝细胞核因子-6增加可以减轻肝细胞凋亡和阻止肝脏疾病的进程。HNF6具有明显的调节肝细胞凋亡的机制。在不同类型肝损伤中肝细胞核因子-6的病理生理作用可能是抗凋亡和保护肝脏。故肝细胞核因子6的增强形态是肝脏疾病一种新型的治疗干预。
关键词: 干细胞凋亡,肝细胞核因子-6,肝损伤,核因子。
Current Molecular Medicine
Title:Pathophysiological Role of Hepatocyte Nuclear Factor 6 in Negative Regulation of Hepatic Apoptosis: A Novel Hypothesis
Volume: 15 Issue: 5
Author(s): K. Wang
Affiliation:
关键词: 干细胞凋亡,肝细胞核因子-6,肝损伤,核因子。
摘要: Apoptosis is a prominent characteristic in the pathogenesis of liver disease. The molecular mechanism of hepatic apoptosis is not well understood. Liver injury induces a downregulation of hepatocyte nuclear factor 6 (HNF6) that is negatively correlated with the degree of apoptosis. However, an enhancement of HNF6 can relieve hepatic apoptosis and impede the progression of liver disease. HNF6 has distinct mechanisms to modulate hepatic apoptosis. Pathophysiological role of HNF6 may be apoptosis-resistant and liver-protective during different types of liver injury. The enhancing modality of HNF6 is a novel therapeutic intervention for liver disease.
Export Options
About this article
Cite this article as:
K. Wang , Pathophysiological Role of Hepatocyte Nuclear Factor 6 in Negative Regulation of Hepatic Apoptosis: A Novel Hypothesis, Current Molecular Medicine 2015; 15 (5) . https://dx.doi.org/10.2174/1566524015666150630124142
DOI https://dx.doi.org/10.2174/1566524015666150630124142 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design High Survivin Expression in Ductal Carcinoma In Situ (DCIS): A Potential Therapeutic Target
Current Cancer Therapy Reviews Latest Advances in Breast Sonography
Recent Patents on Medical Imaging Current Treatment of Relapsed Ovarian Carcinoma
Current Cancer Therapy Reviews Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design The Effect of Quercetin on Doxorubicin Cytotoxicity in Human Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets
CNS & Neurological Disorders - Drug Targets Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Antioxidant Potential of Solvent Partitioned Extraction from Aqueous Extract of Gracilaria Tenuistipitata
Current Organic Chemistry Peripheral TRPV1 Receptors As Targets for Drug Development: New Molecules and Mechanisms
Current Pharmaceutical Design Involvement of Membrane Channels in Autoimmune Disorders
Current Pharmaceutical Design Significance of Prion and Prion-Like Proteins in Cancer Development, Progression and Multi-Drug Resistance
Current Cancer Drug Targets Recent Advances and Novel Approaches for Nose to Brain Drug Delivery for Treatment of Migraine
Drug Delivery Letters Effects of Lipid-Lowering Drugs on Adiponectin
Current Vascular Pharmacology Antiviral Drugs in the Prophylaxis of HBV Infection
Current Medicinal Chemistry Antifolates - Past, Present and Future
Current Medicinal Chemistry - Anti-Cancer Agents YB-1 Protein and Multidrug Resistance of Tumor Cells
Current Signal Transduction Therapy Sugars that Glow in the Dark: Fluorescent Tagged Glucose Bioprobes and their Facilitation of the Drug Discovery Process
Current Medicinal Chemistry MicroRNAs as Potential Targets for Treatment of Osteoclast-Related Diseases
Current Drug Targets CDK9: Therapeutic Perspective in HCC Therapy
Current Cancer Drug Targets